Boston, MA, 03/31/2014 (usastockreports)- Sanofi SA (ADR) (NYSE:SNY) seems to be in for a bumpy ride. On the one hand there is the imminent patent expiry of Lantus in 2015. To put things in perspective, this one drug alone helps generate 17% of Sanofi’s revenue. On the other hand Sanofi is expecting encouraging results from final clinical results for its new vaccine against dengue by late September.
Diabetes wonder drug on the anvil
U300 is the new vaccine which is being touted as Lantus’s successor. Given the positive results so far have given the company enough hope of breaking the effects of Lantus’s expiry.
U300 would be competing with Novo Nordisk’s Tresiba and MannKind’s (MNKD) Afrezza as the next step in replacing insulin from the line of diabetes treatment.
Sanofi bets a billion Euros on Dengue
After spending almost a billion Euros and 20 years in research, Sanofi is set to release its drug in September, pending regulatory approval. The drug, currently undergoing human trials (Phase III) is being tested on 30,000 children across age group 2-16 in Latin America and tropical Asia.
Upon approval, Sanofi SA (ADR) (NYSE:SNY)’s drug would be one of the few, if not the only drug which would be used as vaccine for this disease. Sanofi is confident of receiving regulatory approval and believes it has a blockbuster in hand.
The drug maker’s confidence stems from the fact that dengue alone kills approximately 100 million people annually. Thus, there would be huge demand for the drug in emerging markets like India, Brazil, Mexico, Malaysia, Indonesia and other tropical and subtropical countries. Sanofi SA (ADR) (NYSE:SNY) is so confident that it has already spent EUR 300 million at a facility near Lyon, France and has started producing the drug since July 2013, and is ready to sell from late 2015 subject to regulatory approval.